Released Nov 13, 2019, after the close
10-Q filed Nov 13, 2019, 44 days after period end · 0001213900-19-023231
Q3 2019 · 10-Q
Revenue—
Net Income-$8.55M-$8.55M no prior Q3 2018 on fileN/M vs Q2 2019
EPS Diluted-$1.27-$1.27 no prior Q3 2018 on fileN/M vs Q2 2019
Operating Income-$8,383,000—
Operating Cash Flowderived-$6,704,000—
Free Cash Flowderived-$6,731,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q3 2018 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR